New injection for high blood pressure enters first human safety study

NCT ID NCT06501586

Completed Disease control Sponsor: Suzhou Sanegene Bio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a single dose of SGB-3908, an experimental injectable drug, in 40 healthy volunteers and people with mild high blood pressure. The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in a blood protein linked to blood pressure regulation. This is a first step to see if the drug is safe enough for further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGB-3908
What this could lead to: If successful, this could point toward a new injectable treatment for high blood pressure that works by targeting a key protein.
What could go wrong: This is a very early Phase 1 trial with only 40 people, focused on safety. It is too soon to know if it will work for blood pressure control, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION,ESSENTIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension essential hypertension, genetic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION,ESSENTIAL

Contacts and locations

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, 100083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.